Epertinib (S-222611) is a reversible inhibitor of HER2, EGFR and HER4, that demonstrated more potent effect compared to lapatinib, as well as antitumor activity in a brain metastasis model of HER-positive breast cancer in preclinical studies [178,179]. This evidence concerns the gene ERBB4 and breast carcinoma.